Spero Therapeutics (SPRO) Was Downgraded to a Hold Rating at Evercore ISI

TipRanksDec 23 08:05 · Ratings

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

BenzingaDec 20 19:40 · Ratings

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner

Zacks Dec 17 06:45

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

Zacks Dec 16 22:05

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Zacks Dec 12 22:35

STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Zacks Dec 5 22:40